Proven Process Medical Devices said today it was selected by novel ablation developer Innoblative Designs to act as a partner to develop and manufacture their ablation device.
Innoblative, originally incubated at Northwestern University’s Center for Device Development, is developing the device to allow operating physicians to ablate surgical margins post excision.
“Innoblative’s impressive early-stage success to date underscores their efforts in developing a game-changing device. We are excited to partner with Innoblative on the development of this surgical device, which complements Proven Process’ existing portfolio of medical device solutions designed to enhance the patient experience and the quality of care they receive,” Proven Process prez Ken Fine said in prepared remarks.
Proven Process will operate as partner for product development and manufacturing, as well as aiding in pursuing FDA regulatory clearance for the device.
In November, Proven Process said it signed on to develop and manufacture a cell implant device for Giner used to administer cell therapies for indications such as liver failure, Parkinson’s disease, parathyroid disease, pancreatectomy and Type 1 diabetes.
Giner is developing a miniaturized implantable electrochemical oxygen generator to continuously supply oxygen to islets or cells in an immunoisolation cell implant device, Mansfield, Mass.-based Proven Process said.
The company hopes to use the platform in a BioArtificial Pancreas with an implantable oxygen supply to treat Type 1 diabetes.